{"id":"NCT01845649","sponsor":"Warner Chilcott","briefTitle":"Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia","officialTitle":"A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women With Dyspareunia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-12","primaryCompletion":"2013-11-20","completion":"2013-11-20","firstPosted":"2013-05-03","resultsPosted":"2022-05-09","lastUpdate":"2022-05-09"},"enrollment":550,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Vulvovaginal Atrophy"],"interventions":[{"type":"DRUG","name":"WC3011 Estradiol Vaginal Cream","otherNames":["WC3011"]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Vehicle (3 Times/Week)","type":"ACTIVE_COMPARATOR"},{"label":"WC3011 Estradiol Vaginal Cream (3 Times/Week)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.","primaryOutcome":{"measure":"Change From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment","timeFrame":"Baseline (Day 0) to final assessment (Up to Week 12)","effectByArm":[{"arm":"Vehicle (3 Times/Week)","deltaMin":2.7,"sd":0.44},{"arm":"WC3011 Estradiol Vaginal Cream (3 Times/Week)","deltaMin":2.7,"sd":0.45}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":57,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":271},"commonTop":["Urinary tract infection","Vulvovaginal mycotic infection","Application site pain"]}}